Nanotechnology Now

• About Us
  
  • Advertising
  • Our Mission
  • Our Team
  • Comments
  • Friends
  • Contact
• Nanotechnology
• News
  
  • Current News
  • Press Releases
  • Submit Press
  • Press kit
  • Interviews
• Columns
• Products
  
  • Our Products
  • Books
  • Featured Books
• Directories
  
  • Companies/Academic
  • Events
  • Glossary
  • Best Of
• Career Center
• Nano-Social Network
• Nano Consulting
• My Account

Home > News > Selecta's Series B Adds $15M to Advance Targeted Nanoparticles

February 25th, 2009

Selecta's Series B Adds $15M to Advance Targeted Nanoparticles

Abstract:
Financings Roundup Founded in late 2007 to develop a technology platform that combines discoveries in immunobiology with advances in nanotechnology, Selecta Biosciences Inc. is ready to start moving its program toward the clinic thanks to a $15.1 million Series B round.

"We were gratified to find a very receptive audience at a very difficult time," said Robert Bratzler, executive chairman of the Watertown, Mass.-based firm. He called the Series B "our first substantial round," following $2.5 million in seed funding in May 2008 from Polaris Venture Partners and Flagship Ventures.

Both of those investors returned for the Series B, joined by NanoDimension, a VC firm that focuses on nanotechnologies, and individual investor Timothy A. Springer, a professor of pathology at Harvard Medical School and previous founder of LeukoSite Inc., which was acquired by Millennium Pharmaceuticals Inc. in 1999.

Source:
tmcnet.com

Bookmark:

Related News Press

News and information

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013

Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory June 8th, 2013

CRIXlabs Joins the ROCK Health Incubator: ROCK Health is the world’s leading healthcare incubator looking to make meaningful change through scalable, innovative technology. June 5th, 2013

Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home: Glowing Plant seeks funds via crowdfunding and raises almost $400,000 May 31st, 2013

Investments/IPO's/Splits

Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013

Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013

Long Island Capital Alliance Announces Participants for Biotech Technology Transfer Capital Forum: Event to Be Held on June 14 in Collaboration With Cold Spring Harbor Laboratory June 8th, 2013

Iran to Hold Int'l Forum on Nanotechnology Economy (IFNE2013) May 30th, 2013

Nanomedicine

3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013

Announcements

Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013

Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013

New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013

Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013